Quantcast

Latest Amphetamines Stories

2014-09-15 08:29:16

PHILADELPHIA, September 15, 2014 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG), the global specialty biopharmaceutical company, announced today that the US Food and Drug Administration (FDA) has accepted for filing with priority review a supplemental New Drug Application (sNDA) for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules (CII) as a treatment for adults with binge eating disorder (BED). The FDA is expected to provide a decision in February 2015, based on the...

2014-07-17 16:25:39

LEXINGTON, Massachusetts, July 17, 2014 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG) today announced top-line results from two Phase 4 efficacy and safety studies of Vyvanse(R) (lisdexamfetamine dimesylate) compared with Concerta (methylphenidate HCl) with a placebo reference arm in adolescents aged 13-17 diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD). In SPD489-406, the forced-dose titration study, Vyvanse was found to be statistically superior to...

2014-06-30 04:21:31

DUBLIN, June 30, 2014 /PRNewswire/ -- Shire plc ("Shire" or the "Company") (LSE: SHP, NASDAQ: SHPG) announces that its Canadian subsidiary(1) has received assessments from the Canadian revenue authorities, entitling it to total cash refunds equivalent to US$410 million(2). Following receipt of the assessments(3), the Company has recorded a net credit to income taxes amounting to US$216 million. This income tax credit will be excluded from Non GAAP income, and will not...

2014-06-25 04:20:59

LEXINGTON, Massachusetts, June 25, 2014 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG) announces that Judge Stanley R. Chesler of the U.S. District Court for the District of New Jersey granted Shire's summary judgment motion in a patent infringement lawsuit, holding that certain claims of the patents protecting Vyvanse(R) (lisdexamfetamine dimesylate) were both infringed and valid. The ruling prevents the five pharmaceutical manufacturers (the ANDA Defendants) who...

2014-06-04 12:30:28

MIDDLESEX, N.J., June 4, 2014 /PRNewswire/ -- CorePharma, LLC ("CorePharma"), a developer, manufacturer, and marketer of targeted generic prescription pharmaceuticals, announced today that it has launched Dextroamphetamine Sulfate Tablets, USP ("Dextroamphetamine"), the generic version of Shire's Dextrostat®. Dextroamphetamine is indicated for the treatment of narcolepsy and attention deficit disorder with hyperactivity. CorePharma received final approval from the U.S. Food and Drug...

2014-04-08 10:48:49

Genetic variants associated with enjoying the effects of d-amphetamine—the active ingredient in Adderall—are also associated with a reduced risk for developing schizophrenia and attention deficit hyperactivity disorder (ADHD), report scientists from the University of Chicago in the Proceedings of the National Academy of Sciences on April 7. The results support a long-standing hypothesis that dopamine, the neurotransmitter connected with the euphoric effects of amphetamine, is related to...

2014-04-07 12:33:42

Contest for adults who struggle with organization PHILADELPHIA, April 7, 2014 /PRNewswire/ -- Shire today announced the launch of the Organize Your Stuff contest, which is designed for adults who want help organizing their space and reducing clutter. The contest includes the support of expert organizer Monica Friel, president and founder of Chaos to Order, a respected professional organizing service. To enter, adults ages 18 and over can submit a photo to OrganizeYourStuffContest.com. The...

2014-04-02 08:28:50

NEWPORT BEACH, Calif., April 2, 2014 /PRNewswire/ -- As warm weather, Spring Break, and the kick-off of seasonal music festivals is upon us, so are the dangers of so-called party drugs that fuel many people's fun. Unfortunately, the use of both legal and illegal substances--under party settings in particular--can spark overdoses, hospitalizations, and in some cases exacerbate addiction or mental health issues. Popular party drugs include cocaine, ketamine, MDMA (in different forms),...

2014-02-28 14:09:54

With up to 10 new designer drugs flooding streets every year, more education is needed to convey risks, especially among youth, say UAlberta researchers. In the span of a decade, Canada has gone from ecstasy importer to global supplier of the illegal party drug. At the same time, even newer designer highs—sometimes just a mouse-click away—are flooding the drug market faster than legislation can keep pace. It’s a worrying problem that University of Alberta researchers say requires...

2014-02-25 08:32:17

TORONTO, Feb. 25, 2014 /PRNewswire/ - Highland Therapeutics Inc. ("Highland"), an emerging pharmaceutical company, today announced that the Company's President and Chief Executive Officer, David Lickrish, will present at the 34(th) Annual Cowen and Company Health Care Conference at the Boston Marriott Copley Place in Boston, MA. Highland's presentation is scheduled for Monday, March 3, 2014 at 11:00am EST. A live webcast of the presentation can be accessed by visiting...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.